Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

BBT002

Other · developed by Bambusa Therapeutics

Phase 1/2 Most advanced trial
BBTX Developer
1 Registered trials

What is BBT002?

BBT002 is an investigational agent studied in chronic rhinosinusitis with nasal polyps.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Other
Therapy area
Ear, nose & throat
Developer
Bambusa Therapeutics (BBTX)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07436949 Phase 1/2 Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) Recruiting BBTX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)

More from Bambusa Therapeutics

Sources

Updated Nov 8, 2026. Something wrong or missing? Report it on the BBTX page.

Follow BBTX, the company behind BBT002

See BBTX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

BBTX catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.